GLP-1s show signs of slowing biological ageing, say drugmakers

Novo Nordisk and Eli Lilly presented data at the ARDD 2026 ageing research conference at Harvard (October 1–3) suggesting GLP-1 drugs such as semaglutide and tirzepatide can turn back "ageing clock" measures by roughly 2–3 years, according to an MIT Technology Review report of October 6. The presentations cited SELECT and SURMOUNT-5 but have not been peer-reviewed, and the ageing-clock findings are preliminary and hypothesis-generating. A key open question is whether the effect comes from weight loss rather than the drugs themselves.